+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

EHA Advanced Research Grant

European Hematology Association

The EHA Advanced Research Grant is a type of EHA Research Grant, which can provide up to €240,000 for three years.

Specific criteria for the EHA Advanced Research Grant

Our Advanced Research Grant is suitable for researchers who:

Are currently carrying out basic or translational lab-based research in hematology
Received a PhD or PharmD less than eight years before the closing date listed above
Have at least one first author publication

If you received your PhD or PharmD outside of this timeframe, please check our policy on life events. If this policy applies to you, you can ask us to extend the period of eligibility.

Topics-in-Focus Research Grants: If your research focuses on hemoglobinopathies, you will have a competitive advantage in the selection process. Please select the ‘Topics-in-Focus Advanced Research Grant’ on your application form.

Extending the reach of our grants: If you are operating in countries less-represented among EHA grantees, you will have a competitive advantage in the selection process.

AI Based Application Success Predictor

1. Direct relevance to hematology and laboratory-based research (highest predictor)

This is the most important predictor.

Eligible projects should focus on:

Benign hematology
Hematologic malignancies
Stem cell biology
Hemostasis and thrombosis
Hemoglobinopathies
Bone marrow failure
Transfusion medicine
Immunohematology
Precision hematology

EHA Research Grants specifically support basic and translational laboratory-based hematology research. Purely clinical research, health economics, and other non-laboratory-based projects are generally not eligible, unless they involve a strong translational laboratory component linked to a clinical trial.

2. Scientific significance and impact (very high predictor)

External reviewers explicitly assess the significance and impact of the proposed research.

Competitive proposals should address:

An important unmet need
A major biological or clinical question
Problems with broad relevance to hematology
Research capable of advancing the field

Projects should clearly explain why the work matters and how it could change hematology research or patient care.

3. Innovation and originality (very high predictor)

Novelty is one of the principal review criteria.

Strong proposals typically include:

Novel concepts
Innovative methodologies
New disease mechanisms
Emerging technologies
Creative experimental approaches
High-risk/high-gain ideas

Reviewers explicitly evaluate whether the objectives are ambitious and beyond the current state of the art.

4. Rigorous methodology and feasibility (very high predictor)

Applications should demonstrate:

Clear hypotheses
Appropriate experimental design
Robust methodology
Sound statistical planning
Realistic milestones
Feasible timelines

Reviewers explicitly score both the appropriateness of methods and the feasibility of the proposal.

5. Strong translational potential (very high predictor)

EHA emphasizes research that bridges laboratory discoveries with clinical application.

Competitive projects often involve:

Biomarker development
Precision hematology
Translational studies
Functional genomics
Target validation
Preclinical therapeutic development

While basic science is fully supported, applications are strengthened by a clear pathway toward future clinical benefit.

6. Outstanding investigator track record and potential (very high predictor)

Reviewers explicitly evaluate:

Publication record
International standing
Scientific expertise
Leadership potential
Research productivity

For junior grants, the emphasis is on future independence and leadership potential, while advanced grants place greater weight on an established research record.

7. Excellent host institution and scientific environment (very high predictor)

The quality of the research environment is an explicit review criterion.

Strong applications demonstrate:

A leading academic research center
Appropriate infrastructure
Access to specialized technologies
Strong mentorship
Institutional commitment
Collaborative expertise

Applicants must have support from their academic department and institution. Letters of support should clearly describe the institutional commitment and available facilities.

8. High-quality mentorship and career development (high predictor for junior and physician-scientist awards)

For early-career applicants, EHA requires a mentor letter describing a structured mentoring plan.

Competitive applications demonstrate:

Strong mentorship
Career-development strategy
Research independence plan
Leadership development
Appropriate protected research time (for Physician Scientist Grants)

Mentorship quality is particularly important for Junior Research Grants and Physician Scientist Research Grants.

9. Well-justified and realistic budget (high predictor)

Budget review is an explicit component of evaluation.

Strong budgets should include:

Clear itemization
Appropriate justification
Realistic costs
Alignment with project aims
Efficient use of requested resources

Reviewers assess whether the proposed work can reasonably be completed within the available funding and timeline.

10. Collaboration and future funding potential (high predictor)

Several EHA funding mechanisms—including Innovation Grants, Bilateral Collaborative Grants, and Research Mobility Grants—place special emphasis on collaboration.

Competitive projects often demonstrate:

Complementary expertise
International collaboration
Interdisciplinary partnerships
Potential for future European or international funding
Expansion into larger collaborative research programs

For Innovation Grants, reviewers explicitly evaluate whether the project can support a subsequent application for a larger funding opportunity. Research Mobility Grants likewise prioritize complementary expertise between the home and host institutions to build lasting collaborations.

Specialties

Hematology

Eligibility Requirements

You’re eligible if:

You’re an EHA member
Your institute is an academic research center or proven equivalent in Europe
You have the support of an academic department and institute
Your application relates to basic and translational lab-based research in hematology

Your application will not be eligible if it relates to:

Purely clinical research projects
Projects in health economics
Other non-lab-based research

However, it may be eligible if it relates to the translational part of a clinical trial. In this case, it must be both relevant and novel.

Sponsor Details

Sponsor Institute/Organizations: European Hematology Association

Sponsor Type: Corporate/Non-Profit

Address: Koninginnegracht 12b 2514 AA The Hague

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity